Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study

Figure 1 Patient selection flowchart. G-NETs: Gastric neuroendocrine tumors.

Figure 2 Endoscopic mucosal resection. A: Circumferential marking of the lesion; B: Submucosal injection to create a fluid cushion; C: Resection using a snare; D and E: Targeted coagulation for hemostasis; F: Resected specimen.

Figure 3 Endoscopic submucosal dissection. A: Circumferential marking; B: Submucosal injection for mucosal elevation; C: Mucosal pre-cutting; D: Submucosal dissection for en bloc excision; E: Hemostasis and wound closure; F: Resected specimen.

Figure 4 Progression-free survival curve. A: Progression-free survival curve based on the neutrophil-to-lymphocyte ratio; B: Progression-free survival curve based on somatostatin analog use. Hazards ratio values were derived from Kaplan-Meier calculations. HR: Hazards ratio; CI: Confidence interval; NLR: Neutrophil-to-lymphocyte ratio; SSA: Somatostatin analog.

Figure 5 Baseline information and gene sequencing mutation conditions of 27 patients with type I gastric neuroendocrine tumors. AIG: Autoimmune gastritis; SSAs: Somatostatin analogs; NLR: Neutrophil-to-lymphocyte ratio; FH: Fumarate hydratase; MUTYH: MutY DNA glycosylase; MSH6: MutS homolog 6; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; XRCC3: X-ray repair cross-complementing protein 3; BRCA1: Breast cancer 1.